The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020 3.

Therapies 40

Therapies Disease Treatment FDA Approval 40

Drug Target Review

OCTOBER 1, 2024

At the beginning of my career, during my scholarship, I worked for two years at a research institute where I set up a research project focused on the study of metronomic oral therapies for patients with metastatic breast cancer (BC). That paper, of which I was in the authorship, remains a current point of reference for that therapy usage.

Doctors 97

Doctors Therapies Science Pharma Companies 97

DrugBank

MARCH 15, 2024

The weight loss industry has emerged as a major hub for innovative research, groundbreaking treatments, and economic opportunity. billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. With sales soaring to $2.2 for this class of drugs.

Pharmaceutical Companies 68

Pharmaceutical Companies Pharmaceuticals Treatment Clinical Trials 68

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). This Refinement Therapeutic Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous specific for the treatment of Alzheimer’s trouble with the prospect for at- home administration.”

Disease 52

Disease FDA Therapies Trials 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. Ricks , Lilly chairman and CEO.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

APRIL 24, 2021

In 1999, Novartis launched the first fixed-dose Artemisinin-based Combination Therapy (ACT) and in 2009, the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV). Novartis is advancing Research & Development of next-generation treatments to combat emerging drug resistance.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

NOVEMBER 1, 2020

billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. Currently, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies. About InnoCare Pharma.

Clinical Trials 40

Clinical Trials Trials FDA Treatment 40

Codon

NOVEMBER 3, 2024

In the 1924 novel, The Magic Mountain , Thomas Mann describes a sanatorium patient named Anton Ferge as he undergoes a painful tuberculosis (TB) treatment. But they will need to do so if they want to meet the goals set out by the End TB Strategy , namely, to reduce TB cases by 80 percent and curb deaths by 90 percent before 2030.

Vaccine 85

Vaccine Trials Therapies Treatment 85

The Pharma Data

SEPTEMBER 28, 2020

Developing next-generation therapies. Assessing an innovative therapy for patients with Chagas cardiomyopathy. Less than 1% of affected individuals receive proper anti-parasitic treatment 11 , and current drugs are inadequate to fight the entire spectrum of the disease. Follow us on social media. Novartis Global Health.

Disease 52

Disease Therapies Treatment Clinical Research 52

The Pharma Data

JULY 15, 2021

TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer’s disease in trial participants. The collaboration will introduce a more virtual approach to the evaluation of Alzheimer’s prevention therapies. vice president of pain and neurodegeneration, Lilly.

Trials 52

Trials Therapies Clinical Trials Disease 52

Vial

APRIL 18, 2024

Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. from 2023 to 2030. billion in 2022, is also expected to grow with a CAGR of 7.80% from 2023 to 2030. Dr. Stephen McLeod, M.D.,

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer.”

Therapies 40

Therapies Trials Treatment Disease 40

Vial

MAY 20, 2024

In the field of clinical research , this pipeline can be broken down into several stages and processes specifically designed to rigorously validate the safety and efficacy of new drugs and treatments. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO?

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

FEBRUARY 24, 2022

– Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for heart failure, regardless of ejection fraction. with more than 8 million cases expected by 2030. . with more than 8 million cases expected by 2030.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

JULY 29, 2021

P-tau217 in blood showed promise as additional biomarker of efficacy- Donanemab treatment led to 24% lowering of P-tau217 from baseline. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. In June 2021, Lilly announced the U.S.

Disease 52

Disease Treatment Pharmacokinetics Trials 52

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  Furthermore, AI-powered platforms are being employed to predict antibiotic susceptibility and resistance profiles, enabling the development of personalized treatment strategies that optimize antibiotic use and minimize the risk of resistance emergence. 

Pharmaceutical Companies 72

Pharmaceutical Companies Government Pharmaceuticals DNA 72

The Pharma Data

MARCH 31, 2022

“As an important element of our overall pharmaceutical business strategy we will focus our manufacturing activities on supporting future key areas of growth in which we aim to change the treatment paradigm for patients. All of our company’s new technology platforms and modalities will benefit from this investment.”.

Production 52

Production Pharmaceuticals Science Therapies 52

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

NIH Director's Blog: Drug Development

MAY 15, 2018

In fact, the treatment that cured me would be of little use today. Combination drug therapies including artemisinin have been introduced to take the place of the older drugs [1], but experts are concerned the mosquito-borne parasites that cause malaria are showing signs of drug resistance again. World Health Organization.

Drug Development 52

Drug Development Drugs Disease Treatment 52

The Pharma Data

MARCH 9, 2021

Lilly will present detailed results of the TRAILBLAZER-ALZ phase 2 study, which showed that donanemab treatment resulted in significant slowing of decline in a composite measure of cognition and daily function in people with early symptomatic Alzheimer’s disease (AD) compared to placebo. About Avid Radiopharmaceuticals.

Disease 40

Disease International Research Therapies 40

The Pharma Data

SEPTEMBER 16, 2020

SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%. Weak healthcare systems in LMICs also hinder timely diagnosis and treatment.

Therapies 52

Therapies Regulations Government Disease 52

The Pharma Data

AUGUST 5, 2021

approval; acquisition of Vividion Therapeutics agreed; start of first clinical study for Parkinson’s cell therapy treatment. Food and Drug Administration for the treatment of adult patients with chronic kidney disease and type 2 diabetes. Group sales increase by 12.9 percent (Fx & portfolio adj.) percent to 1.61

Production 52

Production Pharmaceuticals Science Therapies 52

The Pharma Data

MARCH 11, 2021

Sustainability forms an integral part of Bayer’s business strategy, growth plans and incentive systems, Baumann stressed, citing as an example the company’s decision to become carbon-neutral by 2030. One example is the acquisition of Asklepios BioPharmaceutical (AskBio), a leading company in the field of gene therapy.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

MARCH 13, 2021

Donanemab has the potential to become a very important treatment for Alzheimer’s disease. ” Specifically, at 76 weeks compared to baseline, treatment with donanemab slowed decline by 32 percent compared to placebo as measured by the iADRS, which was statistically significant. percent), nausea (10.7 In the donanemab arm, 30.5

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

FEBRUARY 22, 2021

It’s time to make more people aware of TB, remove the stigma associated with the disease, and help those in need of treatment access the best possible care,” said Sarthak Ranade, Managing Director, Janssen India, Johnson & Johnson Private Limited. “At When bedaquiline received its initial accelerated approval by the U.S.

Government 40

Government Disease Treatment International 40

The Pharma Data

APRIL 27, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June 2020 and is listed on the NRDL (National Reimbursement Drug List) as of March 2021. At the end of the first quarter, Dupixent ® was launched in 49 countries with approximately 260 000 patients on therapy. . Neurology and Immunology.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

NOVEMBER 5, 2020

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus. Oncology Program. Praluent ® (alirocumab).

Production 40

Production FDA Trials FDA Approval 40

The Pharma Data

FEBRUARY 8, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June and will be listed on the NRDL (National Reimbursement Drug List) as of March 2021. At the end of 2020, Dupixent ® was launched in 47 countries with approximately 230 000 patients on therapy. Net sales (€ million).

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June and will be listed on the NRDL (National Reimbursement Drug List) as of March 2021. At the end of 2020, Dupixent ® was launched in 47 countries with approximately 230 000 patients on therapy. Net sales (€ million).

Vaccine 52

Vaccine Production FDA Therapies 52

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. Certain IVDs will be treated differently; companion diagnostics used with drug therapies would have to include the international non-proprietary name (INN) of the medicine the test is used with. There were myriad reasons for the extension.

Regulations 40

Regulations International Production Government 40

Codon

OCTOBER 27, 2024

In 2014, the World Health Organization (WHO) proposed an initiative called the End TB Strategy , aimed at reducing cases by 80 percent, deaths by 90 percent, and diagnostic/treatment costs by 100 percent by 2030. In The Magic Mountain , patients receiving this treatment joined what they dubbed the “Half-Lung Club.”

Immune Response 78

Immune Response Doctors Disease Laboratories 78